Application of pure Penicillium viride extract in the preparation of drugs with anti-MRSA activity
By isolating compounds with anti-MRSA activity from the endophytic fungus of Coptis chinensis pure green and Sphinofungin I, the problems of large toxic side effects and strong resistance of existing anti-MRSA drugs are solved, and a low-toxic, novel anti-MRSA drug candidate is provided.
CN117122622BActive Publication Date: 2025-03-28SOUTHWEST UNIV +1
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202311203139.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-18
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2043-09-18
AI Technical Summary
Technical Problem
The existing anti-MRSA drugs have problems such as large toxic side effects, strong drug resistance and lack of new drugs, resulting in unsatisfactory treatment effects and increased drug resistance.
Method used
Compounds with anti-MRSA activity were isolated and identified by extracting from the endophytic fungus Penicillium virgatum and Sphinofungin I, using ethyl acetate extraction, silica gel column chromatography and gradient elution.
Benefits of technology
Effective antagonism of MRSA is achieved, and novel anti-MRSA drug candidates with low toxicity and novel structure are provided, providing valuable bacterial strains and compound resources for clinical treatment.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention belongs to the field of medicine, and specifically discloses an application of a pure green Penicillium extract of fungi in preparing a drug with anti-MRSA activity. The extract is fermented and cultured with pure green Penicillium, then extracted with ethyl acetate, the extract is concentrated into an extract, then the extract is dissolved with ethyl acetate, methanol and water, and then added to a silica gel column for chromatography, and eluted with petroleum ether-ethyl acetate solution, ethyl acetate, methanol or water in different proportions in sequence, the obtained eluate contains active ingredients against methicillin-resistant Staphylococcus aureus, and compounds with significant anti-MRSA activity are obtained through activity tracking, so that new compound resources are provided for the development of new anti-MRSA drugs, and the anti-MRSA treatment is of great significance.
Need to check novelty before this filing date? Find Prior Art